---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-308710"
form_type: "8-K"
ticker: null
cik: "0001971543"
company_name: "Mural Oncology plc"
filed_at: "2025-12-05T23:59:59+00:00"
generated_at: "2026-05-16T14:21:10.682951+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# XOMA Royalty subsidiary completes acquisition of Mural Oncology for $2.035 per share

## Summary
- Scheme of arrangement effective Dec 5, 2025; shareholders receive $2.035 cash per Mural share.
- Mural ordinary shares delisted from Nasdaq; trading suspended before Dec 5 open; Form 25 to be filed.
- Board changes: all prior directors resigned; Owen Hughes (CEO) and Bradley Sitko appointed.
- XOMA Royalty funded the acquisition with cash on hand; no financing contingency.
- Cash consideration distribution to shareholders expected to complete by Dec 19, 2025.

## SEC filing metadata
- accession: 0001193125-25-308710
- form_type: 8-K
- cik: 0001971543
- company_name: Mural Oncology plc
- filed_at: 2025-12-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971543/000119312525308710/0001193125-25-308710-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971543/000119312525308710/d64366d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-308710
- JSON: https://secwatch.observer/filing/0001193125-25-308710.json
- Plain text: https://secwatch.observer/filing/0001193125-25-308710.txt

## Source-grounded claims
- claim_id: dda33151c3c0daa0018175de7563da6720d4e374
  claim: Mural Oncology plc: The Memorandum and Articles of Association were amended pursuant to the Transaction Agreement.
  evidence_excerpt: Pursuant to the terms of the Transaction Agreement, immediately following the Effective Time, the Memorandum and Articles of Association of the Company were amended in accordance with the resolution approved at the EGM, as set forth on Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971543/000119312525308710/0001193125-25-308710-index.htm
- claim_id: c74ca8fc341b6641e6c03ea752625db5a83c9a3f
  claim: Mural Oncology plc underwent a change of control involving XOMA Royalty Corporation and XRA 5 Corp. for $2.035 in cash (closed 2025-12-05).
  evidence_excerpt: the Scheme became effective (the “Effective Time”). At the Effective Time, Sub acquired all of the outstanding ordinary shares, nominal value $0.01 per share, of the Company (the “Ordinary Shares,” and such acquired Ordinary Shares, collectively, the “Mural Shares”) and each holder of Mural Shares outstanding as of 11:59 p.m. Irish local time on December 4, 2025, the business day prior to the occurrence of the Effective Time, obtained the right to receive $2.035 in cash (the “Scheme Consideration”) in exchange for each Mural Share held.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971543/000119312525308710/0001193125-25-308710-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.